Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.

ABSTRACT:

Background

Outcomes for patients with recurrent glioblastoma multiforme (GBM) are poor and may be improved by immunotherapy. We investigated the safety and efficacy of an autologous heat-shock protein peptide complex-96 (HSPPC-96) vaccine for patients with recurrent GBM.

Methods

In this open-label, single-arm, phase II study, adult patients with surgically resectable recurrent GBM were given vaccine after gross total resection. The primary endpoint was overall survival at 6 months. Secondary endpoints included overall survival, progression-free survival, safety, and immune profiling. Outcome analyses were performed in the intention-to-treat and efficacy populations.

Results

Between October 3, 2007 and October 24, 2011, 41 patients underwent gross total resection of re

SUBMITTER: Bloch O 

PROVIDER: S-EPMC3895386 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature